- Joined
- Jan 18, 2013
- Messages
- 152
- Reaction score
- 15
Dear friends, is there any guidelines / publications for the target volume delineation of HAN STS, in the setting of neoadjuvant CRT for an inoperable lesion?
Tx
Tx
Exactly.I don't know of anything in specific. But respect the anatomic boundaries of compartments and I think your contours will end up looking similar to a H&N SCC plan - just add a sup/inf margin (3cm for low grade, 4cm for high grade is what I use) and that margin respects anatomical planes. Axially, your margin will be very tight, but basically encompass a standard H&N volume that is site-dependent.
The more important question here IMO is - what dose are you planning to go to? You stated the lesion is inoperable..is the plan to go to 40-50Gy and reassess? Without surgery, this is probably incurable..could be some tough decisions regarding the final dose and whether to continue chemo down the road..
Normally, you'd want to go to 70 Gy for unresectable scc of the H&N. Sarcoma should receive at least that much, maybe even moreExactly.
I plan to give 50Gy than reassess for resecability. If still inoperable i will try to escalate till 60-66 Gy depending on the tolerance.
Thank you a lot for replying.
I don't know of anything in specific. But respect the anatomic boundaries of compartments and I think your contours will end up looking similar to a H&N SCC plan - just add a sup/inf margin (3cm for low grade, 4cm for high grade is what I use) and that margin respects anatomical planes. Axially, your margin will be very tight, but basically encompass a standard H&N volume that is site-dependent.
The more important question here IMO is - what dose are you planning to go to? You stated the lesion is inoperable..is the plan to go to 40-50Gy and reassess? Without surgery, this is probably incurable..could be some tough decisions regarding the final dose and whether to continue chemo down the road..
I would favor concurrent chemoRT versus induction chemo but depends on histology.
Minimal data for a lot of stuff in unresectable sarcoma, particularly in H&N. I imagine he/she was extrapolating from SCCDo you have data for this? Last time I reviewed this topic, there was minimal data for concurrent chemoRT in sarcoma.
Do you have data for this? Last time I reviewed this topic, there was minimal data for concurrent chemoRT in sarcoma.
what's the histology?Dear friends, is there any guidelines / publications for the target volume delineation of HAN STS, in the setting of neoadjuvant CRT for an inoperable lesion?
Tx